JP2018521120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521120A5 JP2018521120A5 JP2018515193A JP2018515193A JP2018521120A5 JP 2018521120 A5 JP2018521120 A5 JP 2018521120A5 JP 2018515193 A JP2018515193 A JP 2018515193A JP 2018515193 A JP2018515193 A JP 2018515193A JP 2018521120 A5 JP2018521120 A5 JP 2018521120A5
- Authority
- JP
- Japan
- Prior art keywords
- pterygium
- use according
- agent
- inhibitor
- nintedanib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124303 multikinase inhibitor Drugs 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 201000002154 Pterygium Diseases 0.000 claims 10
- -1 canelatinib Chemical compound 0.000 claims 8
- 229960004378 nintedanib Drugs 0.000 claims 6
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 229920000954 Polyglycolide Polymers 0.000 claims 3
- 239000004633 polyglycolic acid Substances 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960002412 cediranib Drugs 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960001602 ceritinib Drugs 0.000 claims 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000008556 epithelial cell proliferation Effects 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 229950005976 tivantinib Drugs 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021066291A JP7234283B2 (ja) | 2015-06-06 | 2021-04-09 | 翼状片を治療するための組成物及び方法 |
| JP2023024878A JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172063P | 2015-06-06 | 2015-06-06 | |
| US62/172,063 | 2015-06-06 | ||
| US201562186660P | 2015-06-30 | 2015-06-30 | |
| US62/186,660 | 2015-06-30 | ||
| PCT/US2016/035726 WO2016200688A1 (en) | 2015-06-06 | 2016-06-03 | Compositions and methods for treating pterygium |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021066291A Division JP7234283B2 (ja) | 2015-06-06 | 2021-04-09 | 翼状片を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521120A JP2018521120A (ja) | 2018-08-02 |
| JP2018521120A5 true JP2018521120A5 (https=) | 2019-07-04 |
| JP6868014B2 JP6868014B2 (ja) | 2021-05-12 |
Family
ID=57504837
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515193A Active JP6868014B2 (ja) | 2015-06-06 | 2016-06-03 | 翼状片を治療するための組成物及び方法 |
| JP2021066291A Active JP7234283B2 (ja) | 2015-06-06 | 2021-04-09 | 翼状片を治療するための組成物及び方法 |
| JP2023024878A Active JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A Active JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A Active JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021066291A Active JP7234283B2 (ja) | 2015-06-06 | 2021-04-09 | 翼状片を治療するための組成物及び方法 |
| JP2023024878A Active JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A Active JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A Active JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US9980901B2 (https=) |
| EP (2) | EP3302379B1 (https=) |
| JP (5) | JP6868014B2 (https=) |
| KR (4) | KR102643821B1 (https=) |
| CN (2) | CN108135737B (https=) |
| AU (3) | AU2016276170B2 (https=) |
| ES (1) | ES2971096T3 (https=) |
| MX (2) | MX393691B (https=) |
| TW (1) | TWI714596B (https=) |
| WO (1) | WO2016200688A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102643821B1 (ko) | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| TWI700085B (zh) * | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| KR102657707B1 (ko) | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
| US11278546B2 (en) | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| JP7018939B2 (ja) * | 2016-09-26 | 2022-02-14 | ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド | 眼疾患の治療のための組成物ならびに使用および調製方法 |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US10335313B2 (en) * | 2017-08-16 | 2019-07-02 | Brian S. Boxer Wachler | Method for removing colored spots to whiten the eye |
| US20200345637A1 (en) * | 2018-01-19 | 2020-11-05 | Aiviva Biopharma, Inc. | Suspension compositions of multi-target inhibitors |
| US20190346048A1 (en) | 2018-05-11 | 2019-11-14 | Quarter Turn Pressure Control, LLC | Replaceable body saver |
| CA3099789A1 (en) * | 2018-05-25 | 2019-11-28 | Cloudbreak Therapeutics Llc | A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same |
| US10941902B2 (en) | 2018-07-10 | 2021-03-09 | Quarter Turn Pressure Control, LLC | Valve grease blocks for high pressure valves and high pressure valves using the same |
| AU2019321429B2 (en) * | 2018-08-15 | 2022-12-08 | Aiviva Biopharma, Inc. | Multi-kinase inhibitors of VEGF and TGF beta and uses thereof |
| EP4349327A3 (en) * | 2018-08-28 | 2024-07-24 | Cloudbreak Therapeutics, LLC | Emulsion formulations of multikinase inhibitors |
| US10744153B1 (en) * | 2019-07-01 | 2020-08-18 | Cloudbreak Therapeutics Llc | Compositions and methods for treating meibomian gland dysfunction |
| BR112021026662A2 (pt) * | 2019-09-10 | 2022-04-12 | Cloudbreak Therapeutics Llc | Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho |
| WO2021165369A1 (en) * | 2020-02-19 | 2021-08-26 | Vestlandets Innovasjonsselskap As | Treatment of corneal vascularisation |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| JP2023527884A (ja) * | 2020-06-01 | 2023-06-30 | エーディーエス・セラピューティクス・エルエルシー | 異常な血管新生を治療するための局所眼科用組成物および方法 |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| CN113425728A (zh) * | 2021-06-29 | 2021-09-24 | 复旦大学附属眼耳鼻喉科医院 | 一种zd6474在翼状胬肉术后抗复发的治疗药物制备中的应用 |
| JP2025525881A (ja) * | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
| AU2022488910A1 (en) * | 2022-12-13 | 2025-06-19 | Suzhou Raymon Pharmaceuticals Company, Ltd. | Use of naphthylurea compounds in preparation of drugs for treating pterygium |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| USD1120038S1 (en) * | 2023-11-30 | 2026-03-24 | J. C. Bamford Excavators Limited | Part of an excavator arm |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739271B2 (en) * | 1997-02-14 | 2001-10-11 | Kissei Pharmaceutical Co. Ltd. | Agents inhibiting progress of pterygium and postoperative recurrence of the same |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| EP2803357B1 (en) * | 2004-06-25 | 2020-11-18 | The Johns-Hopkins University | Angiogenesis inhibitors |
| WO2006020979A2 (en) * | 2004-08-13 | 2006-02-23 | Yale University | Factor vii conjugates for selectively treating neovascularization disorders |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| US20080003219A1 (en) * | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US8558002B2 (en) * | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| RU2518898C2 (ru) | 2007-04-05 | 2014-06-10 | Пфайзер Продактс Инк. | Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у млекопитаюших |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| RU2351298C1 (ru) | 2007-11-27 | 2009-04-10 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ профилактики рецидива птеригиума |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| MX2010013203A (es) | 2008-06-06 | 2011-02-25 | Boehringer Ingelheim Int | Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona. |
| US20100185564A1 (en) | 2009-01-21 | 2010-07-22 | Mccormick & Company, Inc. | Method and questionnaire for measuring consumer emotions associated with products |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
| EP3085358B1 (en) * | 2010-01-22 | 2017-11-01 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| CN102018686B (zh) * | 2010-12-16 | 2012-12-05 | 浙江大学医学院附属邵逸夫医院 | 含有丝裂霉素的膜剂及其制备方法 |
| SG195253A1 (en) | 2011-06-03 | 2013-12-30 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| WO2013000909A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
| KR20140048218A (ko) * | 2011-06-28 | 2014-04-23 | 바이엘 헬스케어 엘엘씨 | 레고라페닙을 함유하는 국소 안과용 약학 조성물 |
| WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| EP2802314B1 (en) | 2012-01-13 | 2020-11-25 | XSpray Microparticles AB | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| CN107115294B (zh) * | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| US20150037422A1 (en) | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| NZ742005A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP2863885A1 (en) * | 2012-06-25 | 2015-04-29 | Bayer HealthCare LLC | Topical ophthalmological pharmaceutical composition containing cediranib |
| EP2863888A1 (en) * | 2012-06-25 | 2015-04-29 | Bayer HealthCare LLC | Topical ophthalmological pharmaceutical composition containing axitinib |
| HK1204992A1 (en) * | 2012-06-25 | 2015-12-11 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sunitinib |
| US20150141448A1 (en) | 2012-06-25 | 2015-05-21 | Bayer Healthcare Llc | Topical Ophthalmological Pharmaceutical Composition containing Pazopanib |
| US10238536B2 (en) | 2012-10-11 | 2019-03-26 | The Regents Of The University Of Colorado, A Body Corporate | Ocular filtration devices, systems and methods |
| EP2916827B1 (en) | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| US8747852B1 (en) | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
| WO2014158863A1 (en) * | 2013-03-14 | 2014-10-02 | Massachusetts Eye And Ear Infirmary | Conjunctival diseases |
| ES2834964T3 (es) * | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| SG10201702674PA (en) * | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| US20140378401A1 (en) | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| US10010610B2 (en) | 2014-01-16 | 2018-07-03 | Retinal Therapies, LLC | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| CN104448300B (zh) * | 2014-12-09 | 2017-01-11 | 西安医学院 | 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用 |
| WO2016123152A1 (en) | 2015-01-26 | 2016-08-04 | University Of Washington | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases |
| KR102643821B1 (ko) * | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| EP3692991A1 (de) | 2015-06-09 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
| TWI700085B (zh) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| WO2017015591A1 (en) | 2015-07-22 | 2017-01-26 | Incept, Llc | Coated punctal plug |
| CN108602879A (zh) | 2016-02-04 | 2018-09-28 | 倪劲松 | 用于治疗疾病的抗体-药物协同作用技术 |
| KR102657707B1 (ko) | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
| US11278546B2 (en) | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| JP7018939B2 (ja) | 2016-09-26 | 2022-02-14 | ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド | 眼疾患の治療のための組成物ならびに使用および調製方法 |
| US11510931B2 (en) | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CN110072849A (zh) | 2017-03-14 | 2019-07-30 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 |
| CA3099789A1 (en) | 2018-05-25 | 2019-11-28 | Cloudbreak Therapeutics Llc | A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same |
| CN110664757B (zh) | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
| BR112021026662A2 (pt) | 2019-09-10 | 2022-04-12 | Cloudbreak Therapeutics Llc | Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho |
| WO2021168218A1 (en) | 2020-02-19 | 2021-08-26 | Clearside Biomedical, Inc. | Compositions comprising axitinib and methods of treating ocular disorders |
| CN116251186B (zh) | 2021-12-09 | 2025-04-25 | 成都瑞沐生物医药科技有限公司 | 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途 |
-
2016
- 2016-06-03 KR KR1020187000359A patent/KR102643821B1/ko active Active
- 2016-06-03 AU AU2016276170A patent/AU2016276170B2/en active Active
- 2016-06-03 KR KR1020247006976A patent/KR20240034866A/ko not_active Ceased
- 2016-06-03 MX MX2017015838A patent/MX393691B/es unknown
- 2016-06-03 WO PCT/US2016/035726 patent/WO2016200688A1/en not_active Ceased
- 2016-06-03 CN CN201680042858.1A patent/CN108135737B/zh active Active
- 2016-06-03 ES ES16808064T patent/ES2971096T3/es active Active
- 2016-06-03 EP EP16808064.6A patent/EP3302379B1/en active Active
- 2016-06-03 KR KR1020267004435A patent/KR20260025887A/ko active Pending
- 2016-06-03 EP EP23210844.9A patent/EP4335418A3/en active Pending
- 2016-06-03 JP JP2018515193A patent/JP6868014B2/ja active Active
- 2016-06-03 KR KR1020247010160A patent/KR102906248B1/ko active Active
- 2016-06-03 CN CN202111180633.1A patent/CN114010787A/zh active Pending
- 2016-06-04 TW TW105117765A patent/TWI714596B/zh active
- 2016-12-12 US US15/375,820 patent/US9980901B2/en active Active
-
2017
- 2017-03-30 US US15/474,620 patent/US9987223B2/en active Active
- 2017-12-06 MX MX2022007989A patent/MX2022007989A/es unknown
-
2018
- 2018-05-29 US US15/991,382 patent/US10149819B2/en active Active
- 2018-05-29 US US15/991,698 patent/US10149820B2/en active Active
- 2018-12-05 US US16/210,896 patent/US10980741B2/en active Active
-
2021
- 2021-04-09 JP JP2021066291A patent/JP7234283B2/ja active Active
- 2021-04-12 US US17/227,877 patent/US12186424B2/en active Active
- 2021-08-20 AU AU2021218212A patent/AU2021218212B2/en active Active
-
2023
- 2023-02-21 JP JP2023024878A patent/JP7571171B2/ja active Active
-
2024
- 2024-02-14 AU AU2024200946A patent/AU2024200946B2/en active Active
- 2024-03-08 JP JP2024035547A patent/JP7838007B2/ja active Active
- 2024-12-04 US US18/968,493 patent/US20250262148A1/en active Pending
-
2025
- 2025-03-19 JP JP2025044397A patent/JP7774170B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521120A5 (https=) | ||
| AU2021218212B2 (en) | Compositions and methods for treating pterygium | |
| JP2021113201A5 (https=) | ||
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| AU2011246574A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| AU2011322597B2 (en) | Dosing regimes for the treatment of ocular vascular disease | |
| JP2024544625A (ja) | がんを処置するためのｃｄｋ２阻害剤およびｃｄｋ４阻害剤を含む方法および投薬レジメン | |
| JPWO2009154169A1 (ja) | ペプチド誘導体およびそれを含む涙液分泌促進組成物 | |
| TW200944518A (en) | Multifunctional ophthalmic compositions | |
| JP5658661B2 (ja) | 手術後癒着の治療のためのヒスタミンｈ４拮抗物質の使用 | |
| TW201427661A (zh) | 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑 | |
| JP2008501778A (ja) | 疼痛の治療のためのレボキセチンの使用 | |
| JP2019515010A5 (https=) | ||
| JP2021063055A (ja) | エドキサバン含有錠剤 | |
| CA2988293C (en) | Compositions and methods for treating pterygium | |
| HK40101374A (en) | Compositions and methods for treating pterygium | |
| HK40116611A (zh) | 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| NZ734516A (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| HK1253895B (en) | Compositions and methods for treating pterygium |